Business Context and Reporting Period
Company: BioLife Solutions, Inc. (BLFS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended September 30, 2024
Business Overview: BioLife develops and supplies bioproduction tools and services for the cell and gene therapy industry, including biopreservation media, automated thawing devices, and storage solutions. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $30,571 | $23,573 | $85,678 | $81,992 |
| Operating Loss | $(1,559) | $(15,475) | $(8,515) | $(34,735) |
| Net Loss (Continuing Ops) | $(1,703) | $(15,804) | $(13,061) | $(30,043) |
| Net Loss (Total) | $(1,703) | $(29,132) | $(32,643) | $(53,045) |
| Diluted EPS (Total) | $(0.04) | $(0.67) | $(0.71) | $(1.22) |
| Cash & Equivalents | $23,977 | $33,317 | $23,977 | $33,317 |
| Total Debt (Current + Long-term) | $20,054 | $25,144 | $20,054 | $25,144 |
| Operating Cash Flow (9M) | $6,786 | $(14,809) | $6,786 | $(14,809) |
Note: Q3 2023 Net Loss includes discontinued operations from Global Cooling. Q3 2024 Net Loss is from continuing operations only as Global Cooling was divested in April 2024.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 30% year-over-year in Q3 2024 ($30.6M vs $23.6M), driven primarily by a 43% increase in cell processing product revenue ($19.0M vs $13.3M). This contrasts with the prior year, which was impacted by customer destocking and reduced biotech funding.
- Profitability Improvement: Operating loss narrowed significantly to $1.6M in Q3 2024 from $15.5M in Q3 2023. The prior year included $8.3M in asset impairment charges and $1.6M in contingent consideration benefits that are not present in the current period.
- Expense Reduction: Operating expenses decreased 18% in Q3 2024. Notable reductions include R&D expenses (down 45%) and Sales & Marketing expenses (down 27%), largely due to headcount reductions.
- Divestiture Impact: The company divested Global Cooling in April 2024, resulting in a $8.9M loss on disposal recorded in the nine months ended Sept 30, 2024. Global Cooling results are now classified as discontinued operations.
- Investment Impairment: The company recognized a $4.1M impairment charge on its equity investment in iVexSol, Inc. during the second quarter of 2024 due to going concern issues.
Guidance, Outlook, and Risks
- Subsequent Event (SciSafe Divestiture): On November 12, 2024, the company entered into an agreement to sell SciSafe for $73.0 million. The company expects to recognize a pre-tax gain of approximately $39.6 million (before goodwill allocation) and anticipates Discontinued Operations treatment in the 2024 10-K.
- Liquidity: Management believes current cash, cash equivalents, and available-for-sale securities ($39.3M as of Sept 30, 2024) are sufficient to meet liquidity needs for at least the next 12 months.
- Debt Obligations: The company has a Term Loan maturing in June 2026 with an implied interest rate of 7.5%. A significant portion of debt ($11.7M) is due in 2025.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, due to material weaknesses in internal control over financial reporting, including insufficient qualified resources and ineffective monitoring controls.
- Risk Factors: Risks include dependence on a limited number of customers (Customer A represented 16% of revenue in Q3 2024), reliance on biotech funding environments, and potential litigation regarding Global Cooling products.
Investor Verification Checklist
- SciSafe Transaction Closing: Verify the final closing terms and actual gain/loss recognized from the SciSafe divestiture announced in November 2024.
- Internal Control Remediation: Monitor progress on remediation plans for material weaknesses in internal controls over financial reporting.
- Debt Maturity Profile: Review the company's ability to service or refinance the $11.7M in debt maturing in 2025.
- Customer Concentration: Assess the impact of potential loss or reduction in orders from top customers (Customer A and B).
- Discontinued Operations: Confirm the final accounting treatment and any remaining liabilities associated with the Global Cooling divestiture.